RxDoctor Payments Data

Frances Estrada

Family · Paramus, NJNPI 1831584713

Payments from drug & device makers

$3,629in general payments, 2019–2025

Across 59 payments — averaging $61.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$849
  • AbbVie$807
  • Neurocrine Biosciences, Inc.$568
  • Vanda Pharmaceuticals Inc.$244
  • E.r. Squibb & Sons, L.L.C.$243
  • Axsome Therapeutics, Inc.$234
  • plus $684 from 6 others

What the payments were for

  • Food & beverage$3,629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,629 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,937
Medicare patients
26
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl20$29,725
Aripiprazole22$1,101
Bupropion XlBupropion Hcl55$1,022
Oxcarbazepine31$966
Escitalopram Oxalate68$672
Duloxetine Hcl68$669
Clonazepam75$628
Divalproex Sodium13$448
Sertraline Hcl107$445
Alprazolam72$442
Quetiapine Fumarate37$386
Venlafaxine Hcl ErVenlafaxine Hcl23$371
Mirtazapine27$346
Quetiapine Fumarate ErQuetiapine Fumarate13$321
Trazodone Hcl43$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$807$29,72520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →